3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
26
Breast
5
Thoracic
4
Genitourinary
4
Gynecologic
3
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Dermatologic
1
Classical hematology
1
Conditions
Sarcoma
8
Melanoma
3
Hemangiosarcoma
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Osteosarcoma
2
Neoplasms
2
Leiomyosarcoma
2
Carcinosarcoma
2
Carcinoma, Endometrioid
2
Vascular Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Synovial
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Liposarcoma
1
Kidney Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hemangioendothelioma, Epithelioid
1
Interventions
Gemcitabine
9
pembrolizumab
7
Irinotecan
5
Docetaxel
4
Cisplatin
4
Carboplatin
4
Capecitabine
4
Albumin-Bound Paclitaxel
4
Paclitaxel
3
Oxaliplatin
3
Leucovorin
3
Cyclophosphamide
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
pazopanib
2
palbociclib
2
liposomal doxorubicin
2
entrectinib
2
alectinib
2
Vinorelbine
2
Trastuzumab
2
Taxes
2
Radiosurgery
2
Oncolytic Virotherapy
2
Observation
2
Ipilimumab
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Erlotinib Hydrochloride
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
durvalumab
×
Sarcoma
×
Clear all
NCT04705818
2026-03-06
CAIRE
Institut Bergonié
Phase 2
Completed
164 enrolled